I would have as much chance of getting that right as picking the...

I would have as much chance of getting that right as picking the Melbourne Cup winner now. A lot can be inferred, using Q121 and Q421 results as outliers, and trying to draw a long bow on known and unknown elements

Some of these are:

What is known:
1. Fantastic product, award winner
2. Increased sales and marketing budget
3. 100k+ units globally
4. Increased medical institutions coming on board in a trial capacity. Increased industrial use as well
5. 15% increase in sales from a low base in first month of Q122

What isn't known
1. Consumable spend per unit and utilisation current 100k+ units globally
2. Penetration into the medical and industrial markets in Europe and USA via their distributor network
3. Current sales in first quarter - an update would be great.
4. Will the lockdowns ending drive the steady growth required due to the end of the disproportionate vaccine drive, increased focus on PPE, rundown of excessive N95 stock, and increased sales push.

At this EV and cash balance I am happy to go along on this one. Management team have the runs on the board with RESMED and Nanosonics. Lets see....